

**GPTHEALTH/CS/SE/2026-27**

**August 3, 2026**

|                                                                                                                                                           |                                                                                                                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>The Department of Corporate Services</b><br>BSE Limited,<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street<br>Mumbai - 400001<br><b>Scrip Code: 544131</b> | <b>National Stock Exchange of India Limited</b><br>Exchange Plaza, Plot no. C/1, G Block,<br>Bandra-Kurla Complex, Bandra (E),<br>Mumbai - 400 051<br><b>Scrip Symbol: GPTHEALTH</b> |
| <b>ISIN: INE486R01017</b>                                                                                                                                 |                                                                                                                                                                                      |

Dear Sir/Madam

**Sub: Press Release on Un-Audited Financial Results for the 1<sup>st</sup> quarter ended on June 30, 2026:**

In compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Company's Code of Practices and Procedure for Fair Disclosure of Unpublished Price Sensitive Information, kindly find enclosed herewith a press release on the Un-Audited Financial Results for the 1<sup>st</sup> quarter ended on June 30, 2026.

Kindly take the aforesaid information on record and oblige.

Thanking You,

Yours sincerely,

**For GPT Healthcare Limited**

**Ankur Sharma**  
**Company Secretary and Compliance Officer**  
**M. No A31833**

Encl. As Above.

**Total Income for Q1FY27 stood at Rs 128 crore**  
a growth of 18% y-o-y

Kolkata, August 3, 2026: GPT Healthcare Limited (GPT) (BSE: 544131 ; NSE: GPTHEALTH) reported its unaudited financial result for the financial year 2026 ended June 30, 2026.

**Total Income**  
**128.2 Cr**

**EBITDA**  
**26.2 Cr**

**PAT**  
**12.7 Cr**

**Key Financial Highlights : Q1 FY27**

| Particulars (Rs. Crs) | Q1FY27 | Q1FY26 | Y-o-Y | Q4FY26 | Q-o-Q  | FY26  |
|-----------------------|--------|--------|-------|--------|--------|-------|
| Total Income          | 128.2  | 108.7  | 18.0% | 128.0  | 0.2%   | 478.5 |
| EBITDA                | 26.2   | 18.9   | 38.5% | 25.0   | 4.9%   | 90.1  |
| EBITDA Margin (%)     | 20.4%  | 17.4%  |       | 19.5%  |        | 18.8% |
| Profit After Tax      | 12.7   | 7.7    | 65.7% | 14.6   | -12.6% | 42.2  |
| PAT Margin (%)        | 9.9%   | 7.1%   |       | 11.4%  |        | 8.8%  |

**Key Operational Highlights for Q1 FY27:**

- The Company maintained a competitive and affordable ARPOB at INR 42,350 while recording steady improvement in occupancy rates at 58.07% (excl. the newly commenced Raipur facility) , driven by higher patient volumes and efficient capacity utilization. Including the Raipur facility, the overall occupancy stands at 45.5%.
- ILS Dum Dum completed over 700+ renal transplants,
- ILS Howrah launched Robotic Knee Surgery programme (MAKO system).
- ILS Agartala delivered over 700 radiation therapy procedures,
- ILS Salt Lake surpassed 800 robotic surgeries.
- ILS Raipur received its liver transplant license and is expected to break even by Q3 FY27.
- The Jamshedpur hospital remains on track for completion by Q4 FY27.
- Participation in the BEMAKI acute kidney injury trial strengthened the Company's clinical research footprint.

**Commenting on the performance, GPT Healthcare Chairman, Dr. Om Tantia, said:**

“During the quarter, GPT Healthcare continued to advance its long-term growth strategy by improving occupancy across mature hospitals, progressively ramping up newer facilities, and strengthening its presence in underserved, high-density markets. The Company focused on expanding high-value specialties, introducing services aligned with patient demand, and increasing the adoption of robotic-assisted and minimally invasive procedures. It also strengthened its doctor and insurance networks, further enhancing patient access and supporting volumes during the period. In line with its capital-efficient expansion strategy, the Company is in the process of finalizing its seventh hospital, which is expected to increase the network’s total capacity to more than 1,000 beds. Supported by standardized clinical governance and ongoing improvements in care quality, patient outcomes, and operational efficiency, these initiatives are expected to unlock operating leverage and deliver sustainable returns while preserving the Company’s net-debt-free position.

**About GPT Healthcare Limited (GPT):**

GPT Healthcare Limited is listed on National Stock Exchange of India Limited and BSE Limited under Symbol: GPTHEALTH, and Scrip Code: 544131, respectively.

GPT Healthcare Limited, the healthcare arm of the GPT Group, operates the ILS Hospitals brand, a leading neighbourhood tertiary-care hospital platform in Eastern India. Established in 2000, the Company currently owns and operates five multi-specialty hospitals—at ILS Salt Lake (85 bed), ILS Agartala (205 bed), ILS Dumdum (155 bed), ILS Howrah (116 bed), and ILS Raipur (158 bed)—each equipped with modern infrastructure and comprehensive clinical capabilities that enable the delivery of end-to-end medical solutions. Collectively, the network commands a capacity of over 719 beds across key Eastern Indian markets, strategically located within high-density residential catchments, while consistently maintaining its affordable care positioning.

The Company follows a proximity-based, capital-efficient operating model designed to enhance accessibility, enable faster occupancy ramp-up, and ensure strong control over clinical outcomes and operating metrics. Its hospitals offer advanced tertiary care services across key specialties including oncology, cardiology, renal transplants, and robotic surgeries, underpinned by standardized clinical governance, robust operating processes, and experienced medical leadership.

For more information about the company, please visit: <http://www.ilshospitals.com>

For further information, contact: GPT Healthcare Ltd | Phone: +91 33 4050 7000 | Email: [ghl.cosec@gptgroup.co.in](mailto:ghl.cosec@gptgroup.co.in)



CIN :L70101WB1989PLC047402

[ir@gptgroup.co.in](mailto:ir@gptgroup.co.in)



Ms. Sejal Bhattar

Mr. Nikunj Seth

[sejal.bhattar@in.mpms.mufg.com](mailto:sejal.bhattar@in.mpms.mufg.com)

[nikunj.seth@in.mpms.mufg.com](mailto:nikunj.seth@in.mpms.mufg.com)